Boston Scientific

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our target at $61, 26.5x our 2024 EPS estimate, a premium to BSX’s historical forward average due to our expectations for accelerating growth. We lift our 2023 EPS estimate by $0.07 to $2.03 and 2024’s by $0.08 to $2.30. BSX posted Q3 EPS of $0.50 vs. $0.43 (+16% Y/Y), $0.02 above the consensus and $0.04 above our estimate. Q3 revenue of $3.6B was up a solid 11% Y/Y, or 10% organically, $50M above consensus and $135M above our estimates, again exceeding the high end of the organic guidance range of 7%-9%. Sales growth was broad-based in the 9%-22% range across geographies and business segments, with the exception of Neuromodulation, which saw slower growth (+3.7% Y/Y). Endoscopy (+12.6% Y/Y), Peripheral Interventions (+12.3% Y/Y), and the core […]

Boston Scientific Corporation (NYSE:BSX) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Mike Mahoney – Chairman & CEO Dan Brennan – EVP & CFO Dr. Ken Stein – SVP & Global CMO Lauren Tengler – VP, IR Conference Call Participants Robbie Marcus – J.P. Morgan Joanne Wuensch – Citibank Rick Wise – Stifel Vijay Kumar – Evercore ISI Larry Biegelsen – Wells Fargo Securities Travis Steed – Bank of America Securities Danielle Antalffy – UBS Matt Taylor – Jefferies Josh Jennings – TD Cowen Chris Pasquale – Nephron Research Mike Polark – Wolfe Research Matthew O’Brien – Piper Sandler Operator Good day, and welcome to the Boston Scientific Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please also note, this event is being recorded. I

Boston Scientific (NYSE:BSX) reported Q2 adjusted earnings  of $0.53 per share, up from $0.44 a year earlier. Analysts polled by Capital IQ expected $0.49. Net sales for the quarter ended June 30 were $3.60 billion, compared with $3.24 billion a year earlier. Analysts surveyed by Capital IQ expected $3.50 billion. For Q3, the medical technology company said it expects adjusted EPS of $0.46 to $0.48. Analysts surveyed by Capital IQ project $0.48. The company expects net sales for the quarter to grow from 8.5% to 10.5% compared with a year earlier. For 2023, the company said it now expects adjusted EPS of $1.96 to $2, from the prior outlook of $1.90 to $1.96 Analysts polled by Capital IQ expect $1.96.The company also raised its net sales growth outlook for the year to an 11% to 12% increase, from its previously announced range of 8.5% to 11%.

Boston Scientific (NYSE:BSX) Raises 2023 Adj. EPS Outlook to $1.90-$1.96 From $1.86-$1.93; Boston Scientific (NYSE:BSX) Sees 2Q Sales Up 6.5%-8.5%, Organic Sales Up 7%-9%